Search results
Results from the WOW.Com Content Network
Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply. During the FY 2013–14, the company incurred ₹ 1,285 crore (equivalent to ₹ 21 billion or US$240 million in 2023) on employee benefit expenses.
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. [8]In 1995, the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals, and Cadila Healthcare became the Patel family's holding company.
India's revenue from pharmaceutical exports was $25.3 billion in the 2022-2023 financial year. [7] In terms of the global market, India currently holds an accountable share and is known as the pharmacy of the world. [9] The country is the largest global supplier of generic medicine. [10] India produces more than 50% the world's vaccines. [11]
Cipla, India's No.3 generic drugmaker by sales, reported a better-than-expected quarterly profit on Friday, boosted by strength in its key domestic and North American businesses. The results come ...
HYDERABAD/BENGALURU (Reuters) -Cipla, India's third-largest generics drugmaker by sales, beat first-quarter profit estimates on Friday as it reported higher sales in its North America market ...
This is a list of companies listed on the National Stock Exchange of India (NSE). Contents !–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z !–9 Symbol ...
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. . The company's drugs reach 70 countries [22] with a footprint that covers advanced markets such as USA, Europe, Japan, [23] Australia as well as emerging markets including India, the Philippines and South Africa to name a
Infosys, the country's second-largest information technology services company, plans to set up a new development centre in Indore at an investment of Rs 100 crore in phase one. Pithampur near Indore houses production plants of various pharmaceutical companies like Ipca Laboratories, Cipla, Lupin, Glenmark, and Unichem.